65,437 trials
Chronic Kidney Diseases · Cystic Kidney Disease
Primary: Number of Participants With Change in Radiologist's Lesion Evaluation — 0; 11; 0; 1 Participants
Weight, Body · Diet Habit
Primary: Weight-for-Length Percentile — 44.94; 46.70; 58.69; 48.54 Percentile
Tinnitus
Primary: Tinnitus Functional Index (TFI); Measure of Tinnitus Distress — 48.7; 50.52; 32.13; 28.95 score on a scale
Diabetes Mellitus, Type 2
Primary: Gliclazide AUC — 3.73; 3.29 μgh/mL
Peripheral T-cell Lymphoma · Cutaneous T-cell Lymphoma
Primary: Objective Response Rate (ORR) — 41.2; 31.6 percentage of participants
Lymphedema · Edema
Primary: Change in Limb Volume — -15; -202 mL
Breast Cancer · Ductal Carcinoma in Situ
Primary: Ipsilateral Recurrence Rate — 0 participants
Complex Regional Pain Syndrome
Primary: Change From Baseline in Mean 24-Hour Pain Intensity as Assessed by NPS Score to the End of Part A — -0.74; -1.05 scores on scale
Neisseria Gonorrhoeae Infection
Primary: Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin G (IgG) Concentrations After Immunization — 61.57; 206.2 titers
Multiple Sclerosis
Primary: Responder Rate of B-Cell Depletion at Week 4 — 87.5; 100.0; 87.5; 100.0 percentage of participants
Short Stature
Primary: Predicted Adult Height at Year 3 — 167.8; 169.4 cm
Hepatitis C, Chronic · Non-Alcoholic Fatty Liver Disease
Primary: Cholate Shunt Test — 28.0; 37.6; 33.4 SHUNT %
Diabetic Macular Edema · Retina Vein Occlusion
Primary: Occurrence of Adverse Events (AEs) Across All Study Visits — 7; 10 Participants
Refractory Differentiated Thyroid Gland Carcinoma · Refractory Thyroid Gland Follicular Carcinoma · Refractory Thyroid Gland Hurthle Cell Carcinoma
Primary: Dose Limiting Toxicity — 0; 1; 2 Participants
Cancer · Neoplasm
Primary: Number of Patients With NY-ESO-1 Specific Humoral Immunity as Determined by an Increase in Antibody Titer From Baseline. — 8; 5; 1 Participants